New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
December 27, 2017 – Teva launched an AB-rated generic version of Bristol-Myers Squibb’s Reyataz (atazanavir) 150 mg, 200 mg and 300 mg capsules.
Download PDF
Return to publications
